# Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

> **NCT05274750** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 276 (actual)

## Conditions studied

- Nasal Polyps

## Interventions

- **BIOLOGICAL:** Depemokimab (GSK3511294)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05274750
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-22
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-08-27
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274750, "Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05274750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*